Symbols / VTVT Stock $40.45 +5.06% vTv Therapeutics Inc.
VTVT (Stock) Chart
About
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Stock Fundamentals
Scroll to Statements| Market Cap | 159.32M | Enterprise Value | 413.02M | Income | -26.97M | Sales | — | Book/sh | 5.19 | Cash/sh | 7.17 |
| Dividend Yield | — | Payout | 0.00% | Employees | 26 | IPO | — | P/E | — | Forward P/E | -10.87 |
| PEG | — | P/S | — | P/B | 7.79 | P/C | — | EV/EBITDA | -12.60 | EV/Sales | — |
| Quick Ratio | 13.39 | Current Ratio | 13.54 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -3.20 | EPS next Y | -3.72 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-10 | ROA | -32.00% | ROE | -78.94% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.94M | Shs Float | 2.90M | Short Float | 3.38% |
| Short Ratio | 1.21 | Short Interest | — | 52W High | 44.00 | 52W Low | 14.00 | Beta | 0.40 | Avg Volume | 48.45K |
| Volume | 125.95K | Target Price | $53.33 | Recom | Strong_buy | Prev Close | $38.50 | Price | $40.45 | Change | 5.06% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$53.33
Mean price target
2. Current target
$40.11
Latest analyst target
3. DCF / Fair value
$-67.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$40.11
Low
$44.00
High
$67.00
Mean
$53.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | init | Evercore ISI Group | — → Outperform | $44 |
| 2026-03-11 | reit | BTIG | Buy → Buy | $49 |
| 2026-01-27 | main | BTIG | Buy → Buy | $49 |
| 2026-01-23 | init | Roth Capital | — → Buy | $58 |
| 2026-01-05 | init | TD Cowen | — → Buy | $67 |
| 2025-12-19 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-11-19 | init | BTIG | — → Buy | $40 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-04-09 | init | HC Wainwright & Co. | — → Buy | $36 |
| 2024-12-09 | init | Alliance Global Partners | — → Buy | $35 |
- VTVT vTv Therapeutics posts far narrower Q4 2025 loss than analyst estimates, shares rise modestly. - Margin Improvement - UBND thành phố Hải Phòng hu, 23 Apr 2026 02
- Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High? - Yahoo Finance Mon, 20 Apr 2026 13
- VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill Fri, 17 Apr 2026 07
- VTVT (vTv Therapeutics Inc.) narrower than expected Q4 2025 loss pushes shares 3.73% higher on upbeat investor sentiment. - Crowd Risk Alerts - Xã Vĩnh Công Wed, 22 Apr 2026 15
- New vTv hire gets 4,000 stock options priced at $39.54 - Stock Titan ue, 07 Apr 2026 07
- VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst - Seeking Alpha Sat, 28 Feb 2026 08
- Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Grows By 24.6% - MarketBeat hu, 16 Apr 2026 12
- Liquidity Mapping Around (VTVT) Price Events - Stock Traders Daily ue, 14 Apr 2026 07
- VTVT Forecast, Price Target & Analyst Ratings | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill Fri, 17 Apr 2026 07
- Millennium entities, Israel A. Englander disclose stakes in vTv Therapeutics (VTVT) - Stock Titan hu, 16 Apr 2026 21
- vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat Wed, 15 Apr 2026 10
- VTVT Stock Analysis: vTv Therapeutics Inc. Biotech Rises 2.19 Percent to 40.53 - UBND thành phố Hải Phòng Wed, 01 Apr 2026 07
- VTVT SEC Filings - Vtv Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 07
- vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements - Yahoo Finance ue, 17 Mar 2026 07
- Newsoara pays $20M for global rights to vTv’s PDE4 inflammation drug HPP737 - Stock Titan Mon, 02 Feb 2026 08
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
1.02
|
0.00
-100.00%
|
2.02
|
| Operating Revenue |
|
0.00
-100.00%
|
1.02
|
0.00
-100.00%
|
2.02
|
| Operating Expense |
|
32.81
+30.21%
|
25.20
-1.20%
|
25.50
+3.84%
|
24.56
|
| Research And Development |
|
17.86
+54.69%
|
11.55
-15.07%
|
13.60
+10.02%
|
12.36
|
| Selling General And Administration |
|
14.95
+9.49%
|
13.65
+14.65%
|
11.91
-2.41%
|
12.20
|
| General And Administrative Expense |
|
14.95
+9.49%
|
13.65
+14.65%
|
11.91
-2.41%
|
12.20
|
| Other Gand A |
|
14.95
+9.49%
|
13.65
+14.65%
|
11.91
-2.41%
|
12.20
|
| Total Expenses |
|
32.81
+30.21%
|
25.20
-1.20%
|
25.50
+3.84%
|
24.56
|
| Operating Income |
|
-32.81
-35.68%
|
-24.18
+5.18%
|
-25.50
-13.14%
|
-22.54
|
| Total Operating Income As Reported |
|
-32.81
-35.68%
|
-24.18
+5.18%
|
-25.50
-13.14%
|
-22.54
|
| EBITDA |
|
-31.06
-37.94%
|
-22.52
+12.94%
|
-25.86
-4.43%
|
-24.77
|
| Normalized EBITDA |
|
-31.06
-37.94%
|
-22.52
+12.94%
|
-25.86
-4.43%
|
-24.77
|
| Reconciled Depreciation |
|
0.02
-82.02%
|
0.09
-1.11%
|
0.09
-2.17%
|
0.09
|
| EBIT |
|
-31.07
-37.47%
|
-22.61
+12.90%
|
-25.95
-4.41%
|
-24.86
|
| Net Income |
|
-26.97
-46.11%
|
-18.46
+8.83%
|
-20.25
-5.67%
|
-19.16
|
| Pretax Income |
|
-31.08
-37.49%
|
-22.61
+12.94%
|
-25.97
-4.39%
|
-24.87
|
| Net Non Operating Interest Income Expense |
|
1.86
+19.11%
|
1.56
+240.96%
|
0.46
+36.20%
|
0.34
|
| Interest Expense Non Operating |
|
0.01
|
0.00
-100.00%
|
0.01
-13.33%
|
0.01
|
| Net Interest Income |
|
1.86
+19.11%
|
1.56
+240.96%
|
0.46
+36.20%
|
0.34
|
| Interest Expense |
|
0.01
|
0.00
-100.00%
|
0.01
-13.33%
|
0.01
|
| Interest Income Non Operating |
|
1.87
+19.49%
|
1.56
+231.57%
|
0.47
+34.09%
|
0.35
|
| Interest Income |
|
1.87
+19.49%
|
1.56
+231.57%
|
0.47
+34.09%
|
0.35
|
| Other Income Expense |
|
-0.14
-1460.00%
|
0.01
+101.08%
|
-0.92
+65.43%
|
-2.67
|
| Other Non Operating Income Expenses |
|
-0.14
-1460.00%
|
0.01
+101.08%
|
-0.92
+65.43%
|
-2.67
|
| Tax Provision |
|
0.00
-100.00%
|
0.10
|
0.00
-100.00%
|
0.20
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-31.08
-36.89%
|
-22.70
+12.56%
|
-25.97
-3.56%
|
-25.07
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.97
-46.11%
|
-18.46
+8.83%
|
-20.25
-5.67%
|
-19.16
|
| Net Income From Continuing And Discontinued Operation |
|
-26.97
-46.11%
|
-18.46
+8.83%
|
-20.25
-5.67%
|
-19.16
|
| Net Income Continuous Operations |
|
-31.08
-36.89%
|
-22.70
+12.56%
|
-25.97
-3.56%
|
-25.07
|
| Minority Interests |
|
4.11
-3.23%
|
4.24
-25.77%
|
5.72
-3.27%
|
5.91
|
| Normalized Income |
|
-26.97
-46.11%
|
-18.46
+8.83%
|
-20.25
-5.67%
|
-19.16
|
| Net Income Common Stockholders |
|
-26.97
-46.11%
|
-18.46
+8.83%
|
-20.25
-5.67%
|
-19.16
|
| Diluted EPS |
|
-3.20
+0.00%
|
-3.20
+67.04%
|
-9.71
+6.63%
|
-10.40
|
| Basic EPS |
|
-3.20
+0.00%
|
-3.20
+67.04%
|
-9.71
+6.63%
|
-10.40
|
| Basic Average Shares |
|
8.42
+45.96%
|
5.77
+176.79%
|
2.08
+11.38%
|
1.87
|
| Diluted Average Shares |
|
8.42
+45.96%
|
5.77
+176.79%
|
2.08
+11.38%
|
1.87
|
| Diluted NI Availto Com Stockholders |
|
-26.97
-46.11%
|
-18.46
+8.83%
|
-20.25
-5.67%
|
-19.16
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
89.90
+134.93%
|
38.27
+247.30%
|
11.02
-66.85%
|
33.24
|
| Current Assets |
|
89.89
+135.86%
|
38.11
+257.63%
|
10.66
-60.67%
|
27.09
|
| Cash Cash Equivalents And Short Term Investments |
|
88.93
+142.02%
|
36.75
+289.01%
|
9.45
-22.10%
|
12.13
|
| Cash And Cash Equivalents |
|
88.93
+142.02%
|
36.75
+289.01%
|
9.45
-22.10%
|
12.13
|
| Receivables |
|
—
|
0.06
-39.22%
|
0.10
-99.18%
|
12.42
|
| Accounts Receivable |
|
—
|
0.06
-39.22%
|
0.10
-41.04%
|
0.17
|
| Prepaid Assets |
|
0.74
-37.67%
|
1.19
+7.48%
|
1.11
-56.54%
|
2.55
|
| Current Deferred Assets |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
0.22
+24.57%
|
0.17
|
—
|
—
|
| Total Non Current Assets |
|
0.01
-96.08%
|
0.15
-57.62%
|
0.36
-94.12%
|
6.14
|
| Net PPE |
|
—
|
0.15
-57.62%
|
0.36
-35.07%
|
0.56
|
| Gross PPE |
|
—
|
0.66
-22.05%
|
0.85
-11.02%
|
0.95
|
| Accumulated Depreciation |
|
—
|
-0.51
-4.31%
|
-0.49
-22.67%
|
-0.40
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
0.24
-30.09%
|
0.35
|
| Machinery Furniture Equipment |
|
—
|
0.13
-34.34%
|
0.20
+0.00%
|
0.20
|
| Other Properties |
|
—
|
0.12
-48.77%
|
0.24
-30.09%
|
0.35
|
| Leases |
|
—
|
0.41
+0.00%
|
0.41
+0.00%
|
0.41
|
| Investments And Advances |
|
—
|
—
|
0.00
-100.00%
|
5.59
|
| Long Term Equity Investment |
|
—
|
—
|
0.00
-100.00%
|
5.59
|
| Other Non Current Assets |
|
0.01
-96.08%
|
0.15
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
25.46
+6.25%
|
23.96
-18.95%
|
29.57
+7.91%
|
27.40
|
| Current Liabilities |
|
6.64
+27.81%
|
5.20
-51.07%
|
10.62
+37.77%
|
7.71
|
| Payables And Accrued Expenses |
|
4.48
+27.23%
|
3.52
-59.91%
|
8.78
+34.50%
|
6.53
|
| Payables |
|
1.13
+20.55%
|
0.94
-76.96%
|
4.08
+65.58%
|
2.46
|
| Accounts Payable |
|
1.13
+20.55%
|
0.94
-76.96%
|
4.08
+65.58%
|
2.46
|
| Current Accrued Expenses |
|
3.34
+29.66%
|
2.58
-45.14%
|
4.70
+15.67%
|
4.06
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.08
+37.91%
|
1.51
+2.93%
|
1.47
+86.04%
|
0.79
|
| Current Debt And Capital Lease Obligation |
|
—
|
0.17
-53.06%
|
0.36
-4.76%
|
0.38
|
| Current Debt |
|
—
|
—
|
0.19
-14.73%
|
0.22
|
| Other Current Borrowings |
|
—
|
—
|
0.19
-14.73%
|
0.22
|
| Current Capital Lease Obligation |
|
0.00
-100.00%
|
0.17
+0.00%
|
0.17
+9.74%
|
0.15
|
| Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.02
+0.00%
|
0.02
|
| Current Deferred Revenue |
|
—
|
0.00
-100.00%
|
0.02
+0.00%
|
0.02
|
| Other Current Liabilities |
|
0.08
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
18.82
+0.28%
|
18.77
-0.94%
|
18.95
-3.77%
|
19.69
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.17
-50.00%
|
0.34
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.17
-50.00%
|
0.34
|
| Non Current Deferred Liabilities |
|
18.67
+0.00%
|
18.67
+0.00%
|
18.67
+0.00%
|
18.67
|
| Non Current Deferred Revenue |
|
18.67
+0.00%
|
18.67
+0.00%
|
18.67
+0.00%
|
18.67
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
16.58
|
| Stockholders Equity |
|
64.44
+428.22%
|
12.20
+149.43%
|
-24.68
-129.80%
|
-10.74
|
| Common Stock Equity |
|
64.44
+428.22%
|
12.20
+149.43%
|
-24.68
-129.80%
|
-10.74
|
| Capital Stock |
|
0.04
+21.88%
|
0.03
+18.52%
|
0.03
+0.00%
|
0.03
|
| Common Stock |
|
0.04
+21.88%
|
0.03
+18.52%
|
0.03
+0.00%
|
0.03
|
| Share Issued |
|
3.94
+50.78%
|
2.61
+25.29%
|
2.08
+2.35%
|
2.04
|
| Ordinary Shares Number |
|
3.94
+50.78%
|
2.61
+25.29%
|
2.08
+2.35%
|
2.04
|
| Additional Paid In Capital |
|
391.09
+25.40%
|
311.88
+21.67%
|
256.33
+0.62%
|
254.76
|
| Retained Earnings |
|
-326.69
-9.00%
|
-299.72
-6.65%
|
-281.04
-5.84%
|
-265.52
|
| Minority Interest |
|
0.00
-100.00%
|
2.10
-65.72%
|
6.13
-63.02%
|
16.58
|
| Total Equity Gross Minority Interest |
|
64.44
+350.58%
|
14.30
+177.10%
|
-18.55
-417.67%
|
5.84
|
| Total Capitalization |
|
64.44
+428.22%
|
12.20
+149.43%
|
-24.68
-129.80%
|
-10.74
|
| Working Capital |
|
83.25
+152.91%
|
32.92
+86523.68%
|
0.04
-99.80%
|
19.39
|
| Invested Capital |
|
64.44
+428.22%
|
12.20
+149.81%
|
-24.49
-132.87%
|
-10.52
|
| Total Debt |
|
0.00
-100.00%
|
0.17
-68.05%
|
0.53
-26.12%
|
0.72
|
| Capital Lease Obligations |
|
0.00
-100.00%
|
0.17
-50.00%
|
0.34
-31.30%
|
0.49
|
| Net Tangible Assets |
|
64.44
+428.22%
|
12.20
+149.43%
|
-24.68
-129.80%
|
-10.74
|
| Tangible Book Value |
|
64.44
+428.22%
|
12.20
+149.43%
|
-24.68
-129.80%
|
-10.74
|
| Derivative Product Liabilities |
|
0.15
+52.00%
|
0.10
-9.09%
|
0.11
-83.92%
|
0.68
|
| Notes Receivable |
|
—
|
—
|
0.00
-100.00%
|
12.24
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-25.25
+0.21%
|
-25.31
-32.63%
|
-19.08
-19.09%
|
-16.02
|
| Cash Flow From Continuing Operating Activities |
|
-25.25
+0.21%
|
-25.31
-32.63%
|
-19.08
-19.09%
|
-16.02
|
| Net Income From Continuing Operations |
|
-31.08
-36.89%
|
-22.70
+12.56%
|
-25.97
-3.56%
|
-25.07
|
| Depreciation Amortization Depletion |
|
0.02
-82.02%
|
0.09
-1.11%
|
0.09
-2.17%
|
0.09
|
| Depreciation |
|
0.02
-82.02%
|
0.09
-1.11%
|
0.09
-2.17%
|
0.09
|
| Depreciation And Amortization |
|
0.02
-82.02%
|
0.09
-1.11%
|
0.09
-2.17%
|
0.09
|
| Other Non Cash Items |
|
—
|
—
|
0.21
+163.20%
|
-0.34
|
| Stock Based Compensation |
|
3.77
+36.92%
|
2.76
+74.71%
|
1.58
+24.06%
|
1.27
|
| Asset Impairment Charge |
|
0.00
|
0.00
-100.00%
|
4.25
|
0.00
|
| Operating Gains Losses |
|
0.14
+1520.00%
|
-0.01
+99.72%
|
-3.63
-284.25%
|
-0.95
|
| Gain Loss On Investment Securities |
|
0.14
+1460.00%
|
-0.01
+98.26%
|
-0.57
+39.32%
|
-0.95
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
|
0.00
-100.00%
|
3.58
|
| Gain Loss On Sale Of PPE |
|
0.01
|
0.00
|
0.00
|
—
|
| Change In Working Capital |
|
1.89
+134.79%
|
-5.44
-223.76%
|
4.39
-18.40%
|
5.38
|
| Change In Receivables |
|
—
|
0.04
-43.66%
|
0.07
+161.21%
|
-0.12
|
| Changes In Account Receivables |
|
—
|
0.04
-43.66%
|
0.07
+161.21%
|
-0.12
|
| Change In Prepaid Assets |
|
0.45
+307.87%
|
-0.22
-113.93%
|
1.55
+484.86%
|
-0.40
|
| Change In Payables And Accrued Expense |
|
1.53
+129.34%
|
-5.21
-278.05%
|
2.93
+442.17%
|
-0.86
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
0.00
|
| Change In Payable |
|
—
|
—
|
—
|
-0.86
|
| Change In Account Payable |
|
—
|
—
|
—
|
-0.86
|
| Change In Other Working Capital |
|
—
|
-0.02
|
—
|
6.76
|
| Change In Other Current Assets |
|
0.08
-54.19%
|
0.18
+163.24%
|
0.07
|
0.00
|
| Change In Other Current Liabilities |
|
-0.17
+0.00%
|
-0.17
-9.74%
|
-0.15
|
0.00
|
| Investing Cash Flow |
|
0.00
|
0.00
-100.00%
|
4.40
+21071.43%
|
-0.02
|
| Cash Flow From Continuing Investing Activities |
|
0.00
|
0.00
-100.00%
|
4.40
+21071.43%
|
-0.02
|
| Net PPE Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Purchase Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.02
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
4.40
|
0.00
|
| Gain Loss On Sale Of Business |
|
0.00
|
0.00
+100.00%
|
-3.06
|
0.00
|
| Financing Cash Flow |
|
77.44
+47.21%
|
52.61
+338.50%
|
12.00
-18.69%
|
14.75
|
| Cash Flow From Continuing Financing Activities |
|
77.44
+47.21%
|
52.61
+338.50%
|
12.00
-18.69%
|
14.75
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.19
-478.79%
|
-0.03
-3.13%
|
-0.03
|
| Issuance Of Debt |
|
0.39
|
0.00
-100.00%
|
0.57
-27.06%
|
0.78
|
| Repayment Of Debt |
|
-0.39
-105.24%
|
-0.19
+68.11%
|
-0.60
+25.87%
|
-0.81
|
| Long Term Debt Issuance |
|
0.39
|
0.00
-100.00%
|
0.57
-27.06%
|
0.78
|
| Long Term Debt Payments |
|
—
|
—
|
-0.60
+25.87%
|
-0.81
|
| Net Long Term Debt Issuance |
|
0.39
|
0.00
-100.00%
|
0.57
-27.06%
|
0.78
|
| Short Term Debt Payments |
|
-0.39
-105.24%
|
-0.19
+68.11%
|
-0.60
+25.87%
|
-0.81
|
| Net Short Term Debt Issuance |
|
-0.39
-105.24%
|
-0.19
+68.11%
|
-0.60
+25.87%
|
-0.81
|
| Net Common Stock Issuance |
|
77.48
+46.74%
|
52.80
+338.89%
|
12.03
-18.64%
|
14.79
|
| Proceeds From Stock Option Exercised |
|
0.02
|
0.00
|
0.00
-100.00%
|
9.75
|
| Net Other Financing Charges |
|
-0.05
|
—
|
—
|
—
|
| Changes In Cash |
|
52.19
+91.16%
|
27.30
+1118.66%
|
-2.68
-107.91%
|
-1.29
|
| Beginning Cash Position |
|
36.75
+289.01%
|
9.45
-22.10%
|
12.13
-9.61%
|
13.41
|
| End Cash Position |
|
88.93
+142.02%
|
36.75
+289.01%
|
9.45
-22.10%
|
12.13
|
| Free Cash Flow |
|
-25.25
+0.21%
|
-25.31
-32.63%
|
-19.08
-18.94%
|
-16.04
|
| Interest Paid Supplemental Data |
|
0.01
+200.00%
|
0.00
-85.71%
|
0.01
-6.67%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.10
|
0.00
-100.00%
|
0.20
|
| Change In Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
77.48
+46.74%
|
52.80
+338.89%
|
12.03
-18.64%
|
14.79
|
| Issuance Of Capital Stock |
|
77.48
+46.74%
|
52.80
+338.89%
|
12.03
-18.64%
|
14.79
|
| Sale Of Business |
|
0.00
|
0.00
-100.00%
|
4.40
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-10 View
- 8-K2026-03-10 View
- 10-K2026-03-10 View
- 8-K2026-02-26 View
- 42026-02-18 View
- 42026-02-18 View
- 8-K2026-02-02 View
- 8-K2025-12-19 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 42025-09-25 View
- 8-K2025-09-10 View
- 42025-09-05 View
- 42025-09-05 View
- 8-K2025-09-02 View
- 10-Q2025-08-12 View
- 8-K2025-08-12 View
- 42025-06-12 View
- 42025-06-12 View
- 42025-06-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|